- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A Wyeth-sponsored patient website used 2004 US WHI data and prominent “-6” graphics implying oestrogen-only HRT protected against breast cancer, despite later…
Dexcel’s Deximune mailing and online detail aid emphasised “no dose adjustment” when switching from Neoral, but omitted/underplayed the SPC requirement for close…
Complaint about a US third-party CME follow-up email allegedly promoting Victoza and giving misleading renal impairment safety info. Panel found the email…
Anonymous employee alleged poor global Code training and a questionable advisory board. Panel found breaches for failure to certify and high standards;…
Anonymous complaint alleged a Cipla senior manager pressured switching, linked education support to sales, discussed off-label spacer use, worked exhibition stands without…
Eliquis HCP website listed NSAID/aspirin caution but omitted similar SSRI/SNRI cautions added to the updated SmPC. Panel found the page misleading and…
Diurnal’s health professional webpage combined a licensed product with pipeline products and implied they were “effective, high quality”. PMCPA ruled this promoted…
A GP challenged a Pradaxa journal ad claiming “efficacy and safety equivalent to enoxaparin”. PMCPA ruled the equivalence message (reinforced by balanced…
A Chiesi-sponsored journal handed out from a BTS promotional stand included COPD-focused content and a Fostair ad. The Panel ruled this effectively…
A third-party email promoting a Ferinject video implied other IV irons required multiple hospital visits. PMCPA held Vifor responsible for the distributor…
Merz challenged Allergan’s National Stroke Forum panel claiming “No set dose ratio has been established between BoNT-A formulations”. The PMCPA ruled the…
BMJ analysis suggested Novartis had “due trials” without results on EUCTR. PMCPA found most trials were out of UK Code scope or…
A GP complaint about UK newspaper coverage led to findings that a consumer press release and spokesperson briefing effectively promoted Pradaxa (dabigatran)…
A GP challenged a sponsored Future Prescriber article on linagliptin as misleading pre-licence promotion. PMCPA held Boehringer Ingelheim responsible and found multiple…
PMCPA case AUTH/3073/9/18 (Director v Novartis) concerned clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.